QQ客服 官方微博 反馈留言

	A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo
	Mayer Barbara[1]; Karakhanova Svetlana[2]; Bauer Nathalie[3]; Liu Li[4]; Zhu Yifan[5]; Philippov Pavel P[6]; Werner Jens[7]; Bazhin Alexandr V[8]
刊名	Naunyn-Schmiedeberg's archives of pharmacology
	2017
卷号	390期号:11页码:1125-1134
关键词	Cancer stem cells Epithelial-to-mesenchymal transition PDAC Regorafenib Spheroid tumor model
ISSN号	1432-1912
DOI	http://dx.doi.org/10.1007/s00210-017-1412-1
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/5182635
专题	河南大学
作者单位	1.Department of General, Visceral, and Transplantation Surgery, University Hospital of the LMU, Marchioninistr. 15, 81377, Munich, Germany. 2.Section Surgical Research, University of Heidelberg, Heidelberg, Germany 3.Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany. 4.Department of Oncology, Henan University Huaihe Hospital, Kai Feng, People's Republic of China. 5.Department of Cell Signalling, Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia.
推荐引用方式 GB/T 7714	Mayer Barbara[1],Karakhanova Svetlana[2],Bauer Nathalie[3],et al. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo[J]. Naunyn-Schmiedeberg's archives of pharmacology,2017,390(11):1125-1134.
APA	Mayer Barbara[1].,Karakhanova Svetlana[2].,Bauer Nathalie[3].,Liu Li[4].,Zhu Yifan[5].,...&Bazhin Alexandr V[8].(2017).A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.Naunyn-Schmiedeberg's archives of pharmacology,390(11),1125-1134.
MLA	Mayer Barbara[1],et al."A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo".Naunyn-Schmiedeberg's archives of pharmacology 390.11(2017):1125-1134.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。